文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Immunosuppressive Signaling Pathways as Targeted Cancer Therapies.

作者信息

Setlai Botle Precious, Hull Rodney, Bida Meshack, Durandt Chrisna, Mulaudzi Thanyani Victor, Chatziioannou Aristotelis, Dlamini Zodwa

机构信息

Department of Surgery, Faculty of Health Sciences, University of Pretoria, Private Bag X323, Arcadia 0007, South Africa.

SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield 0028, South Africa.

出版信息

Biomedicines. 2022 Mar 16;10(3):682. doi: 10.3390/biomedicines10030682.


DOI:10.3390/biomedicines10030682
PMID:35327484
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8945019/
Abstract

Immune response has been shown to play an important role in defining patient prognosis and response to cancer treatment. Tumor-induced immunosuppression encouraged the recent development of new chemotherapeutic agents that assists in the augmentation of immune responses. Molecular mechanisms that tumors use to evade immunosurveillance are attributed to their ability to alter antigen processing/presentation pathways and the tumor microenvironment. Cancer cells take advantage of normal molecular and immunoregulatory machinery to survive and thrive. Cancer cells constantly adjust their genetic makeup using several mechanisms such as nucleotide excision repair as well as microsatellite and chromosomal instability, thus giving rise to new variants with reduced immunogenicity and the ability to continue to grow without restrictions. This review will focus on the central molecular signaling pathways involved in immunosuppressive cells and briefly discuss how cancer cells evade immunosurveillance by manipulating antigen processing cells and related proteins. Secondly, the review will discuss how these pathways can be utilized for the implementation of precision medicine and deciphering drug resistance.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/5ce933741eb8/biomedicines-10-00682-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/4b1fa4dd18b2/biomedicines-10-00682-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/f3a1725e854c/biomedicines-10-00682-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/78350de9e6f1/biomedicines-10-00682-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/49c9c1876a92/biomedicines-10-00682-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/895b1bda8d62/biomedicines-10-00682-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/ba4a0ee2174c/biomedicines-10-00682-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/5ce933741eb8/biomedicines-10-00682-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/4b1fa4dd18b2/biomedicines-10-00682-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/f3a1725e854c/biomedicines-10-00682-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/78350de9e6f1/biomedicines-10-00682-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/49c9c1876a92/biomedicines-10-00682-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/895b1bda8d62/biomedicines-10-00682-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/ba4a0ee2174c/biomedicines-10-00682-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9300/8945019/5ce933741eb8/biomedicines-10-00682-g007.jpg

相似文献

[1]
Immunosuppressive Signaling Pathways as Targeted Cancer Therapies.

Biomedicines. 2022-3-16

[2]
Cancer immune escape: the role of antigen presentation machinery.

J Cancer Res Clin Oncol. 2023-8

[3]
Immune evasion of microsatellite unstable colorectal cancers.

Int J Cancer. 2010-9-1

[4]
Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion.

Oncoimmunology. 2019-9-6

[5]
Understanding and overcoming resistance to immunotherapy in genitourinary cancers.

Cancer Biol Ther. 2024-12-31

[6]
Tumor-Infiltrating Dendritic Cells: Decisive Roles in Cancer Immunosurveillance, Immunoediting, and Tumor T Cell Tolerance.

Cells. 2022-10-11

[7]
The mechanisms on evasion of anti-tumor immune responses in gastric cancer.

Front Oncol. 2022-11-10

[8]
At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma.

Front Oral Health. 2021-3-5

[9]
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.

Semin Cancer Biol. 2020-10

[10]
Targeting the immune microenvironment for ovarian cancer therapy.

Front Immunol. 2023

引用本文的文献

[1]
Hallmarks of cellular senescence: biology, mechanisms, regulations.

Exp Mol Med. 2025-7-10

[2]
Prophylactic and therapeutic vaccine development: advancements and challenges.

Mol Biomed. 2024-11-11

[3]
Molecular Mechanism for Malignant Progression of Gastric Cancer Within the Tumor Microenvironment.

Int J Mol Sci. 2024-10-31

[4]
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors.

Cancer Chemother Pharmacol. 2024-7

[5]
Drug resistance mechanisms in cancers: Execution of pro-survival strategies.

J Biomed Res. 2024-2-28

[6]
Direct immunoactivation by chemotherapeutic drugs in cancer treatment.

Adv Ther (Weinh). 2023-12

[7]
Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy.

Cancer Res. 2024-3-15

[8]
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy.

Front Oncol. 2023-6-22

[9]
Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma.

Int J Mol Sci. 2022-8-12

本文引用的文献

[1]
Compromised DNA Repair Promotes the Accumulation of Regulatory T Cells With an Aging-Related Phenotype and Responsiveness.

Front Aging. 2021

[2]
Editorial: Personalized Medicine for Urological Cancers: Targeting Cancer Metabolism.

Front Oncol. 2022-3-3

[3]
mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.

Front Immunol. 2021

[4]
MicroRNA Interrelated Epithelial Mesenchymal Transition (EMT) in Glioblastoma.

Genes (Basel). 2022-1-27

[5]
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression.

Cancer Immunol Immunother. 2022-9

[6]
TGF-β Signaling and Resistance to Cancer Therapy.

Front Cell Dev Biol. 2021-11-30

[7]
Genomic instability, inflammatory signaling and response to cancer immunotherapy.

Biochim Biophys Acta Rev Cancer. 2022-1

[8]
XBP1 regulates the protumoral function of tumor-associated macrophages in human colorectal cancer.

Signal Transduct Target Ther. 2021-10-20

[9]
IL-35 promotes CD4+Foxp3+ Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms.

JCI Insight. 2021-10-8

[10]
Induction of CD4 regulatory T cells by stimulation with Staphylococcal Enterotoxin C2 through different signaling pathways.

Biomed Pharmacother. 2021-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索